
    
      The Sponsor terminated this study due to the need for a modification to the Spiromax device
      utilized in this study; the problem identified has no impact on patient safety. Exposure
      ranged from 3 to 49 days with the majority of subjects receiving â‰¤30 days of double-blind
      treatment.
    
  